Coherus Biosciences | CHRS - Sales Revenues


Coherus Biosciences reported $7.6M in Sales Revenues for its fiscal quarter ending in March of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Akebia Therapeutics USD 57.34M 10.84M Mar/2025
ALKERMES USD 384.5M 9.7M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amarin USD 49.67M 23.07M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Baxter International USD 2.97B 130M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Coherus Biosciences USD 7.6M 46.54M Mar/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Fujifilm JPY 857.35B 34.47B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Ironwood Pharmaceuticals USD 47.71M 74.35M Dec/2025
Merck USD 16.4B 880M Dec/2025
Myriad Genetics USD 209.8M 4.1M Dec/2025
Pacira USD 196.87M 17.35M Dec/2025
Perrigo USD 1.11B 70M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025
Zoetis USD 2.4B 0 Dec/2025